This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
Ironwood (IRWD) Q2 Loss Widens, Revenues Miss, Stock Up
by Zacks Equity Research
Ironwood Pharmaceuticals' (IRWD) second-quarter results were dismal, missing sales and earnings estimates.
Ironwood (IRWD) Reports Positive Data on Reflux Candidate
by Zacks Equity Research
Ironwood's GI candidate met the primary endpoint of a phase IIb study. It showed significant reduction in weekly heartburn severity in adult patients with reflux disease.
Allergan Reports Positive New Data on Irritable Bowl Drug
by Zacks Equity Research
Allergan plc (AGN) has announced positive data from a pooled analysis of two phase III studies, evaluating its marketed drug Viberzi (eluxadoline) for treatment of adults suffering from irritable bowel syndrome with diarrhea (IBS-D).
Why Is Ironwood (IRWD) Up 6.9% Since the Last Earnings Report?
by Zacks Equity Research
Ironwood (IRWD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Allergan's Irritable Bowel Drug Viberzi Approved in Canada
by Zacks Equity Research
Allergan plc (AGN) announced that Health Canada approved Viberzi (eluxadoline) for the treatment of adults suffering with irritable bowel syndrome with diarrhea (IBS-D)
Ironwood (IRWD) Q1 Loss Wider than Expected, Sales Miss
by Zacks Equity Research
Ironwood Pharmaceuticals, Inc. (IRWD) reported first-quarter 2017 adjusted loss of 33 cents per share, significantly wider than both the Zacks Consensus Estimate of a loss of 19 cents and the year-ago loss of 8 cents.
Are Options Traders Betting on a Big Move in Ironwood Pharmaceuticals (IRWD) Stock?
by Zacks Equity Research
Huge implied volatility makes Ironwood Pharmaceuticals (IRWD) Stock lucrative to the option traders.
Ironwood (IRWD) Q4 Loss Narrower than Expected; Sales Top
by Zacks Equity Research
Ironwood Pharmaceuticals, Inc. (IRWD) reported an adjusted loss of 12 cents per share in the fourth quarter of 2016, narrower than the Zacks Consensus Estimate of a loss of 23 cents but slightly wider than the year-ago loss of 11 cents.
Drug Stocks Q4 Earnings Lineup for Feb 21: IRWD, MNTA, EXAS
by Zacks Equity Research
Here we have three pharma companies that are set to report fourth-quarter results on Feb 21. Let's see how things are shaping up for this quarter.
Radius Health (RDUS) Q4 Earnings: Will the Stock Disappoint?
by Zacks Equity Research
Radius Health, Inc. (RDUS) is scheduled to report fourth-quarter 2016 financial results on Feb 23.
5 Drug Stocks Poised to Beat Earnings Estimates in Q4
by Arpita Dutt
Medical is one of the few sectors that has consistently recorded earnings growth over the last 4 quarters. Here is a look at 5 pharma and biotech stocks that look set to beat Q4 earnings estimates.
Ironwood/Astellas Report Positive Phase III Data on Linzess
by Zacks Equity Research
Ironwood (IRWD) and partner Astellas reported positive top-line data from a phase III study on Linzess in adults with chronic constipation.
Ironwood-Allergan Linzess Gets FDA Approval in Lower Dose
by Zacks Equity Research
Ironwood Pharmaceuticals, Inc. (IRWD) and partner Allergan plc (AGN) announced that the FDA has approved a lower dose strength of Linzess (linaclotide) ??? 72 mcg ??? for the treatment of adult patients with chronic idiopathic constipation (CIC).
Ironwood, Allergan Report Positive Linzess IBS-C Study Data
by Zacks Equity Research
Ironwood (IRWD) and Allergan (AGN) report phase IIb study data on colonic release formulations of Linzess for the treatment of irritable bowel syndrome with constipation.